Nanogen Announces Collaboration with Canadian Agencies to Develop Veterinary and Bioterror Diagnostics
Advertisement
Nanogen, Inc. announced that it has received project funding from several Canadian agencies, including the Canadian food Inspection Agency (CFIA). The purpose of the funding and collaborative agreement is to develop diagnostic tools for the detection of natural or potential bioterror threats to livestock, such as foot and mouth disease and avian flu, employing the company's NanoChip(R) platform.
"Although the majority of our NanoChip(R) instruments are used in basic research and human clinical diagnostics applications, we have always known that the platform's flexibility confers benefit in other markets, such as veterinary diagnostics and the monitoring of bioterror threats," said Nanogen president and chief operating officer David Ludvigson.
The project, titled "Adaptation of Recently Developed DNA Microarrays to NanoChip Microarray Technology for Detection of Agroterrorism Agents" was approved by Defence Research and Development Canada through the CRTI Program (CBRNE (Chemical, Biological, Radiological, and Nuclear) Research and Technology Initiative (CRTI). Financial terms were not disclosed. Additional collaborators include the CFIA's laboratory in Lethbridge, Alberta and the National Center for Foreign Animal Diseases located in Winnipeg, Manitoba.
Most read news
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine
Köhler_disease
Consortium lead by Prophylix Pharma AS receives up to €6 M in EU-funding - The EU grant is for development of a prophylactic treatment to prevent severe bleeding and death in newborns caused by Fetal/Neonatal Alloimmune Trombocytopenia
Progress in pursuit of sickle cell cure
Analytik Jena Opens Swiss Branch Office at the Endress+Hauser Headquarters

The Origin of Life in membraneless protocells - Researchers show that membraneless microdroplets are a great place for RNA concentration and activity to enable the origin of life
